Also trades as QIA.DE.
QGEN
BuyPremium GrowerAI neutralQiagen N.V. · Healthcare · Netherlands · $10.4B cap · $215.8M/day traded
$50.37 -0.0% · close 26 Oct · scored 24 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
Report expected 4 Nov: the next-year EPS estimate has been little changed over the last 14 weeks.
As of 24 Oct 2026, MoatMap's StockRank for Qiagen N.V. (QGEN) is 79/100, ranked against 24,000+ stocks in 35 markets (Quality 63, Value 48, Momentum 63, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Qiagen supplies sample preparation and molecular testing products with a large recurring consumables base. Product momentum is steady, including FDA clearance that completes its QIAstat-Dx bloodstream infection portfolio in the US and the new QIAmini automation system. The shares rose on a report of private equity takeover interest, which supports the valuation floor but is not a confirmed offer. Growth has been modest since the pandemic testing peak and no macro theme favours the business in particular.
ABOUT QIAGEN N.V.
Read
Qiagen N.V. is a global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from biological samples. The company's key products include sample technologies, diagnostic assays, and bioinformatics software used in molecular diagnostics and life sciences research. Qiagen maintains a leading market position through its proprietary consumables, which generate highly recurring revenue streams.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.1B | 2.0B | 2.0B | 2.1B | -0.8% | 2.1B | 2.1B | 2.2B | 3.6% |
| EPS | 2.82 | 1.67 | 0.41 | 2.06 | -10.0% | 1.97 | 2.11 | 2.26 | 4.8% |
| Shares | 204.0M | 204.4M | 205.3M | 206.1M | +1.0% | 206.5M | — | — | — |
| Debt | 1.9B | 1.5B | 1.5B | 1.8B | -1.3% | 1.7B | — | — | — |
| Equity | 3.5B | 3.8B | 3.6B | 3.8B | 2.9% | — | — | — | — |
| Op CF | 715.3M | 459.5M | 673.6M | 654.3M | -2.9% | 654.5M | — | — | — |
| Inv CF | -726.8M | -87.7M | -249.2M | -305.3M | — | — | — | — | — |
| Fin CF | -125.8M | -433.8M | -422.9M | -179.0M | — | — | — | — | — |
Above its 200-day average and 12% below its 52-week high.
Calmer than 61% of stocks we rank over the past year (36% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of QGEN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| QGEN | Qiagen N.V.(you) | $10.4B | 79 | Buy |
| PHG | Koninklijke Philips N.V. | $26.3B | 85 | Strong Buy |
| ARGX.BR | argenx SE | $55.1B | 84 | Strong Buy |
| RDC.DE | Redcare Pharmacy NV | $1.8B | 62 | Hold |
| PHARM.AS | Pharming Group N.V. | $803M | 37 | Hold |
| NAMS | NewAmsterdam Pharma Company N.V. | $2.3B | 10 | Strong Sell |
| QURE | uniQure N.V. | $1.6B | 16 | Strong Sell |
| PRQR | ProQR Therapeutics N.V. | $182M | 17 | Strong Sell |
| ONWD.BR | Onward Medical N.V. | $161M | 11 | Strong Sell |
Peer medians: ROE 3.6% · P/E 30.9x · Gross margin 75.4%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.